CAR T-cell Therapy

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Latest News

FDA hematology approvals
Hematologic Oncology Field Sees Almost 20 FDA Approvals in 2024

February 11th 2025

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

Marginal Zone Lymphoma | Image Credit: © LASZLO – stock.adobe.com
Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.
Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

Sattva S. Neelapu, MD
Axi-Cel Shows Durable Responses, May Have Curative Potential in R/R Indolent Non-Hodgkin Lymphoma

February 4th 2025

Saurabh Dahiya, MD, FACP
Secondary Primary Cancer Prevention Strategies Following CAR T-Cell Therapy Are Underway

February 4th 2025

More News